Bernstein: AstraZeneca’s Non‑Oncology Franchise May Be Undervalued by Investors
Bernstein says AstraZeneca’s non-oncology division could drive the majority of the company’s midterm growth, estimating higher revenues than consensus and highlighting large gaps between its own forecasts and market expectations for several late-stage and approved products. The broker retains an outperform rating and a price target implying roughly…